OP04 Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial
Simon Travis(University of Oxford), Bo Shen(Soochow University), Mark Löwenberg(Amsterdam University Medical Centers), Allan R Escher(Takeda (Switzerland)), Silvio Danese(IRCCS Ospedale San Raffaele), Brian G. Feagan(Western University), Brian Bressler(University of British Columbia), Dirk Lindner(Takeda (United States)), Paolo Gionchetti(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Mark S. Silverberg(Sinai Health System), Siân Jones(Swansea University), Vipul Jairath(Western University)
Cited by 11
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k